Wall Street brokerages expect Oxford Immunotec Global PLC (NASDAQ:OXFD) to post sales of $30.17 million for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Oxford Immunotec Global PLC’s earnings, with the highest sales estimate coming in at $30.29 million and the lowest estimate coming in at $30.05 million. Oxford Immunotec Global PLC reported sales of $26.11 million during the same quarter last year, which indicates a positive year-over-year growth rate of 15.5%. The business is scheduled to issue its next quarterly earnings report on Tuesday, November 7th.

According to Zacks, analysts expect that Oxford Immunotec Global PLC will report full-year sales of $30.17 million for the current year, with estimates ranging from $103.40 million to $104.58 million. For the next year, analysts anticipate that the firm will post sales of $122.27 million per share, with estimates ranging from $120.43 million to $123.39 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Oxford Immunotec Global PLC.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last announced its quarterly earnings data on Tuesday, August 1st. The company reported ($0.32) earnings per share for the quarter, hitting the consensus estimate of ($0.32). Oxford Immunotec Global PLC had a negative return on equity of 35.76% and a negative net margin of 34.58%. The company had revenue of $26.10 million during the quarter, compared to analyst estimates of $25.05 million. During the same quarter last year, the firm posted ($0.29) EPS. The firm’s revenue for the quarter was up 35.9% on a year-over-year basis.

A number of research analysts have recently issued reports on OXFD shares. BTIG Research reaffirmed a “buy” rating on shares of Oxford Immunotec Global PLC in a report on Thursday, May 4th. Zacks Investment Research cut Oxford Immunotec Global PLC from a “buy” rating to a “hold” rating in a research report on Wednesday, May 3rd. ValuEngine upgraded Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Cowen and Company reiterated a “buy” rating and set a $22.00 price objective on shares of Oxford Immunotec Global PLC in a research report on Thursday, August 3rd. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $26.00 price objective on shares of Oxford Immunotec Global PLC in a research report on Thursday, August 3rd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. Oxford Immunotec Global PLC has an average rating of “Hold” and an average price target of $21.00.

ILLEGAL ACTIVITY WARNING: “Zacks: Analysts Anticipate Oxford Immunotec Global PLC (NASDAQ:OXFD) Will Post Quarterly Sales of $30.17 Million” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/zacks-analysts-anticipate-oxford-immunotec-global-plc-nasdaqoxfd-will-post-quarterly-sales-of-30-17-million/1471909.html.

In related news, CEO Peter Wrighton-Smith sold 32,832 shares of the company’s stock in a transaction on Wednesday, July 5th. The stock was sold at an average price of $16.58, for a total transaction of $544,354.56. Following the completion of the sale, the chief executive officer now owns 478,106 shares in the company, valued at $7,926,997.48. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Peter Edwardson sold 22,371 shares of the company’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $17.70, for a total value of $395,966.70. Following the sale, the chief operating officer now owns 102,644 shares of the company’s stock, valued at approximately $1,816,798.80. The disclosure for this sale can be found here. In the last quarter, insiders have sold 126,456 shares of company stock valued at $2,063,095. 7.58% of the stock is owned by company insiders.

Hedge funds have recently bought and sold shares of the stock. Wells Fargo & Company MN boosted its stake in Oxford Immunotec Global PLC by 129.2% in the first quarter. Wells Fargo & Company MN now owns 65,937 shares of the company’s stock worth $1,021,000 after buying an additional 37,163 shares during the period. State Street Corp boosted its stake in Oxford Immunotec Global PLC by 22.2% in the fourth quarter. State Street Corp now owns 320,599 shares of the company’s stock worth $4,792,000 after buying an additional 58,340 shares during the period. Neuberger Berman Group LLC boosted its stake in Oxford Immunotec Global PLC by 143.6% in the first quarter. Neuberger Berman Group LLC now owns 134,229 shares of the company’s stock worth $2,079,000 after buying an additional 79,129 shares during the period. TFS Capital LLC boosted its stake in Oxford Immunotec Global PLC by 19.8% in the first quarter. TFS Capital LLC now owns 14,125 shares of the company’s stock worth $219,000 after buying an additional 2,337 shares during the period. Finally, United Services Automobile Association purchased a new stake in Oxford Immunotec Global PLC during the first quarter worth approximately $1,599,000. Institutional investors own 87.03% of the company’s stock.

Shares of Oxford Immunotec Global PLC (NASDAQ OXFD) opened at 17.13 on Friday. The stock’s market cap is $395.29 million. Oxford Immunotec Global PLC has a one year low of $8.88 and a one year high of $19.51. The company has a 50-day moving average price of $16.74 and a 200 day moving average price of $15.10.

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Get a free copy of the Zacks research report on Oxford Immunotec Global PLC (OXFD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.